In the final part of this slideshow series, take a look back at the novel drugs and therapeutics approved by the FDA in 2023,1 including treatments for ulcerative colitis, neutropenia, desmoid tumors, and more.
Guselkumab Shows Positive Results in Trials for Crohn’s Disease, Ulcerative Colitis
October 10th 2024Guselkumab is currently approved by the FDA to treat adults with moderate to severe plaque psoriasis, adults with active psoriatic arthritis, and adults with moderately to severely active ulcerative colitis.